Skip to main content
. 2020 Apr;23(4):515–526. doi: 10.22038/ijbms.2020.40401.9563

Figure 2.

Antioxidant activity assays in ovarian tissues of all experimental groups

Figure 2

A) glutathione (GSH) levels, B) superoxidedismutase (SOD) levels, C) total antioxidant capacity (TAC), D) malondialdehyde (MDA) levels, E) total oxidative stress (TOS) and F) oxidative stress index (OSI). The data represent means±SD (n=10/group). Cisplatin administration significantly reduced ovarian GSH concentration (P<0.001), SOD activity (P<0.001) and TAC (P<0.001) compared to control rats. Added to that, cisplatin significantly increased MDA (P<0.001), TOS (P<0.001) and OSI (P<0.001) compared to control group. Royal jelly (RJ) significantly restored the ovarian antioxidant activity, which was indicated by the significant increase of ovarian GSH concentration (P<0.001), SOD activity (P<0.001) and TAC (P<0.001) compared to cisplatin-treated rats. Also, RJ significantly reduced the ovarian MDA (P<0.001), TOS (P<0.001) and OSI (P<0.001) compared to cisplatin group. a: indicates a significant difference when compared to the control group at P<0.05, b: indicates a significant difference when compared to cisplatin group at P<0.05